News

Using AI to Analyze Gait May Help Diagnose Parkinson’s Disease

New machine learning models based on walking patterns accurately distinguished between Parkinson’s patients and healthy people, and between different stages of the disease, a study showed. “We chose gait parameters as the key criteria because gait impairments appear early in Parkinson’s and get worse over time, and also because…

Krill Oil Reduces Hallmarks of Parkinson’s Disease in Animal Model

Krill oil, which comes from a shrimp-like animal, protected dopamine-producing neurons from age-related degeneration and boosted neurologic processes dependent on the brain chemical messenger in a worm model of Parkinson’s disease, a study showed. The production of dopamine is gradually impaired in people with Parkinson’s due to the progressive…

ABBV-951 Found to Help Control Motor Symptoms in Phase 3 Trial

ABBV-951, a continuous infusion formulation of levodopa/carbidopa that’s administered under the skin, improved “on” time and decreased “off” time when compared with standard oral therapy in people with advanced Parkinson’s disease. Those are the results of a randomized Phase 3 clinical trial testing the experimental formulation in more than…

Metabolon, Tracking Parkinson’s Unite to ID Disease Progression

Metabolon is teaming up with Tracking Parkinson’s, the world’s largest long-term study into Parkinson’s disease, to identify novel metabolic biomarkers of disease progression. The discoveries may lead to personalized treatments and better patient care. “We are extremely enthusiastic about partnering with Tracking Parkinson’s to further the understanding…

Experimental Therapy Anle138b Shows Promise as Diagnostic Tracer

The small molecule anle138b, an experimental therapy for Parkinson’s disease, was shown in a study to bind to lipidic (fat) fibrils in alpha-synuclein protein clumps, suggesting it could also offer a new diagnostic approach for the disease. “The promising drug candidate anle138b … binds to lipidic alpha-synuclein structures. The drug…

FDA Clears Parky App, Device to Monitor Motor Symptoms

The U.S. Food and Drug Administration (FDA) has given h2o therapeutics 510(k) marketing clearance for its Parky app that monitors motor symptoms in Parkinson’s patients via measurements recorded by an Apple Watch. “As a woman-founded, non [venture capital]-backed company based in Turkey, receiving our first 510(k) clearance is…

Online Educational Series for Healthcare Professionals Begins

The Parkinson’s Foundation has launched a new education series for healthcare professionals to improve the treatment and health outcomes of people with Parkinson’s disease. The Education Series for Community Providers, developed in collaboration with the CVS Health Foundation, seeks to expand patients’ access to high quality healthcare…